Skip to content
Wednesday 19 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE · FR
MorningWire

European business, markets and politics

FTSE 100
10,743.35
+0.14%
DAX
26,091.33
-0.14%
CAC 40
8,501.91
-0.09%
STOXX 50
6,444.46
-0.37%
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
More
GermanyFranceEU InstitutionsCompetitionPublic AffairsBankingTechnologyEnergy
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
  • DE
Friday 03 September 2021 5:51 pm  |  Updated:  Thursday 04 November 2021 10:28 am

Covid jabs for healthy teens not recommended by UK vaccine body

By: Millie Turner and Amy O'Brien

Add as a preferred source on Google
Women receives Pfizer vaccine
Capitalism was fundamental in the pandemic. We have to safeguard it, explaining why it does good to people (Photo by Hollie Adams/Getty Images)

The Joint Committee on Vaccine and Immunisation (JCVI), which advises the government on its jab rollout, has decided not to recommend Covid vaccines for healthy 12 to 15-year-olds.

After an assessment that focused on health grounds alone, the JCVI has now referred the matter to the UK’s four chief medical officers to review.

The JCVI has previously referred 200,000 under-16s with underlying health conditions to receive the Pfizer/BioNTech vaccine, due to being considered ‘clinically vulnerable’.

But the body decided that there was no overwhelming benefit to the vaccine for healthy children, who are at very low risk of complications due to Covid.

England’s four chief medical officers will now determine other non-health factors that may benefit children if they receive the vaccine – for example, the question of missing out on school.

In a statement following the JCVI advice, the UK’s four chief medical officers confirmed they will review the wider issues affecting children and present their advice to ministers on whether a universal programme should be taken forward.

“People aged 12 to 15 who are clinically vulnerable to the virus have already been offered a COVID-19 vaccine, and today we’ll be expanding the offer to those with conditions such as sickle cell disease or type 1 diabetes to protect even more vulnerable children,” health secretary Sajid Javid said.

“We will [..] consider the advice from the Chief Medical Officers, building on the advice from the JCVI, before making a decision shortly.”

Read more

ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer

Covid-19 positivity rates were highest in the teenager and young adult age group in the week to 27 August, according to the Office for National Statistics.

However, hospital admissions and deaths remained highest among the elderly, a trend seen throughout the pandemic.

The risk of death for children not considered ‘high risk’, with underlying health conditions, has been extremely rare since the pandemic began in the country last year.

In deciding against a vaccine rollout for teens, the UK will have a bolstered supply for both the global vaccine sharing scheme COVAX as well as booster jabs for immunosuppressed adults.

The JCVI, which advises the government on its Covid vaccine strategy, set out the new recommendation for booster jabs separately from potential booster shot programmes, which health secretary Sajid Javid said the government is planning to begin separately in September.

Anyone over the age of 12 who was immunosuppressed at the time of their first or second dose of the Covid vaccine, including those with leukaemia, advanced HIV, or recent organ transplants, will be offered the extra dose.

Around half a million people in the UK are expected to receive a third booster shot.

Read more

Almirall Announces EMA Acceptance for Filing of Paediatric Registration of Ebglyss (Lebrikizumab) in Atopic Dermatitis in Children 6 Months and Older

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Politics
  • Business

Related Topics

  • Coronavirus
  • Vaccine

Trending Articles

  • Jobless Banquet: Youth unemployment surge ‘sends Neets to KFC’

  • As it happened: FTSE 100 drops as oil prices rise after Trump makes Hormuz threat

  • US bond market jitters spark UK economy recession warning

  • Amanda Blanc has worked her magic at Aviva

  • City law firm sues prominent Emirati business family

More from Morning Wire

  • ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer

    Business Wire
  • Almirall Announces EMA Acceptance for Filing of Paediatric Registration of Ebglyss (Lebrikizumab) in Atopic Dermatitis in Children 6 Months and Older

    Business Wire
  • Nanochon Receives Regulatory Approval from Panamá’s Ministry of Health to Initiate First-in-Human Clinical Study of Chondrograft™

    Business Wire
  • Verdiva Bio Appoints Cardiometabolic Leader Steve Marso as Chief Medical Officer

    Business Wire
  • VoxNeuro Receives FDA 510(k) Clearance for Cognitive Function Neuroimaging (cfNI) Software – An Objective EEG/ERP Brain Health Assessment

    Business Wire
  • This Is the Moment Everything Changed: Ascensia Launches Global Art and Photography Competition for World Diabetes Day

    Business Wire
  • Clinigen Appoints Greg Skalicky as Chief Executive Officer

    Business Wire
  • Azalea Vision Appoints Co-Founder Andrés Vasquez Quintero as Chief Executive Officer to Lead Next Phase of Clinical Development

    Business Wire
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • EU Institutions
  • Europe

Business

  • Markets
  • Business
  • Economy
  • Regulation
  • Competition
  • Public Affairs

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook